髓系细胞特异性IL-6信号通过促进富含miR-223的外泌体产生减轻NAFLD相关纤维化
本研究探讨髓系细胞特异性IL-6信号如何通过调控抗纤维化miR-223影响NAFLD。发现NAFLD/NASH患者血清IL-6和sIL-6Rα升高,IL-6水平与循环白细胞和单核细胞数正相关。小鼠实验表明髓系特异性Il6ra敲除导致肝脏浸润巨噬细胞和中性粒细胞减少但纤维化加重,机制涉及miR-223减少及TAZ上调;IL-6处理促进巨噬细胞释放富含miR-223的外泌体,可减少肝细胞促纤维化TAZ表达。结论:髓系IL-6信号通过外泌体转移miR-223抑制肝纤维化。
要点
- NAFLD/NASH患者血清IL-6和sIL-6Rα升高,IL-6与循环白细胞和单核细胞数正相关
- 髓系特异性Il6ra敲除小鼠肝脏浸润巨噬细胞和中性粒细胞减少但肝纤维化加重
- IL-6通过促进巨噬细胞释放富含miR-223的外泌体抑制肝细胞TAZ表达而抗纤维化
核心结论
- 髓系特异性IL-6信号通过外泌体将抗纤维化miR-223转移至肝细胞,抑制肝纤维化,为NAFLD治疗提供靶点。
研究设计与样本
- 招募NAFLD或NASH患者及健康对照,检测血清IL-6和sIL-6Rα。
- 使用Il6敲除和Il6ra条件性敲除小鼠(包括肝细胞特异性和髓系特异性)在高脂饮食喂养下研究IL-6在NAFLD中的作用。
- 体外实验研究IL-6处理对巨噬细胞外泌体生物发生相关基因及miR-223富集外泌体释放的影响。
主要发现
- 与对照相比,NAFLD/NASH患者血清IL-6和sIL-6Rα水平升高,IL-6水平与循环白细胞和单核细胞数正相关。
- 高脂饮食喂养的Il6敲除小鼠较野生型肝损伤和纤维化更重,但炎症更轻。
- 肝细胞特异性Il6ra敲除小鼠脂肪变性和肝损伤加重;髓系特异性Il6ra敲除小鼠肝脏浸润巨噬细胞和中性粒细胞减少伴细胞死亡增加,但肝纤维化加重。
- 髓系特异性Il6ra敲除小鼠肝纤维化加重归因于抗纤维化miR-223减少及miR-223靶基因TAZ上调。
- 体外IL-6处理上调外泌体生物发生相关基因,促进巨噬细胞释放富含miR-223的外泌体,通过外泌体转移减少肝细胞促纤维化TAZ表达。
关键数值与推荐
- NAFLD/NASH患者血清IL-6和sIL-6Rα水平较健康对照升高。
- IL-6水平与循环白细胞和单核细胞数呈正相关。
- 髓系特异性Il6ra敲除小鼠肝纤维化较野生型加重,伴miR-223减少和TAZ上调。
- NAFLD患者血清IL-6和miR-223水平升高且相互相关。
临床怎么用
- 提示髓系IL-6信号通过miR-223外泌体转移发挥抗纤维化作用,可能成为NAFLD纤维化治疗靶点。
- 血清IL-6和miR-223水平在NAFLD患者中升高且相关,但尚需进一步验证其临床价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND ANDS AIMS: NAFLD is associated with elevation of many cytokines, particularly IL-6; however, the role of IL-6 in NAFLD remains obscure. The aim of this study was to examine how myeloid-specific IL-6 signaling affects NAFLD by the regulation of antifibrotic microRNA-223 (miR-223) in myeloid cells. APPROACH AND RESULTS: Patients with NAFLD or NASH and healthy controls were recruited, and serum IL-6 and soluble IL-6 receptor α (sIL-6Rα) were measured. Compared to controls, serum IL-6 and sIL-6Rα levels were elevated in NAFLD/NASH patients. IL-6 levels correlated positively with the number of circulating leukocytes and monocytes. The role of IL-6 in NAFLD was investigated in Il6 knockout (KO) and Il6 receptor A (Il6ra) conditional KO mice after high-fat diet (HFD) feeding. HFD-fed Il6 KO mice had worse liver injury and fibrosis, but less inflammation, compared to wild-type mice. Hepatocyte-specific Il6ra KO mice had more steatosis and liver injury, whereas myeloid-specific Il6ra KO mice had a lower number of hepatic infiltrating macrophages (IMs) and neutrophils with increased cell death of these cells, but greater liver fibrosis (LF), than WT mice. Mechanistically, the increased LF in HFD-fed, myeloid-specific Il6ra KO mice was attributable to the reduction of antifibrotic miR-223 and subsequent up-regulation of the miR-223 target gene, transcriptional activator with PDZ-binding motif (TAZ), a well-known factor to promote NASH fibrosis. In vitro, IL-6 treatment up-regulated exosome biogenesis-related genes and subsequently promoted macrophages to release miR-223-enriched exosomes that were able to reduce profibrotic TAZ expression in hepatocytes by exosomal transfer. Finally, serum IL-6 and miR-223 levels were elevated and correlated with each other in NAFLD patients. CONCLUSIONS: Myeloid-specific IL-6 signaling inhibits LF through exosomal transfer of antifibrotic miR-223 into hepatocytes, providing therapeutic targets for NAFLD therapy.
引用
- Hou X, Yin S, Ren R, et al. Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis. Hepatology. 2021. PMID: 33236445. doi:10.1002/hep.31658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。